This roundup includes a selection of abstracts on early and metastatic breast cancer presented at the 2024 San Antonio Breast ...
Retesting biomarkers is crucial when cancer progression deviates from expected patterns. An expert discusses the next steps ...
The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in ...
"Before, there was that balance of 'what is time worth?' And now, that's taken that stress away somewhat." ...
Researchers at Baylor College of Medicine and Rice University have received a $2.3 million Breakthrough Award from the ...
Sharf, MD, and colleagues will discuss treatment considerations in metastatic ER+ breast cancer at the 2024 SABCS meeting.
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news. If you’re covering the American Society of Hematology (ASH) Annual Meeting, Dec. 7-10 in San ...
Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...
Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...
Researchers also found that metastasis patterns differed by breast cancer subtype. These findings were presented in a poster at the 2024 SNO Annual Meeting. The researchers analyzed 421 patients with ...
SUO annual meeting included a prostate cancer session, featuring a presentation by Dr. Ganesh Palapattu discussing the biology of cancer metastases. Dr. Palapattu started his presentation by ...
Olema Pharmaceuticals, Inc. (OLMA), a clinical-stage biopharmaceutical company, Monday announced a new clinical trial collaboration ...